72067424RFA00006: USAID/Lesotho Bophelo Bo Botle (Good Health) Activity
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of South Africa USAID-Pretoria notices from 2024.
South Africa USAID-Pretoria offered grants of up to $18.3 million (at least $18.3 million) to any type of organization. It expected to make one award. Applications closed on March 15, 2024.
From the official notice on Grants.gov, last changed March 8, 2024. Checked November 7, 2026.
- Award ceiling$18.3 million
- Award floor$18.3 million
- Expected awards1
- Cost sharingRequired
- Funding typeCooperative Agreement
Key dates
| Posted | March 1, 2024 |
|---|---|
| Deadline | March 15, 2024 |
| Archived by Grants.gov | April 14, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $18.3 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- The notice requires cost sharing or matching funds, so you must contribute part of the project cost.
What the grant funds
This NOFO was published as a forecast on February 12, 2024. Amendment 01 is posted now on March 1, 2024 with the answers to the questions received on February 23, 2024. The NOFO has been revised to reflect these answers and it is attached to this Amendment. __________________________________________________________________________________________ Introduction: The Bophelo Bo Botle activity is intended to support the Government of Lesotho (GOL) to improve health outcomes through the delivery high-quality integrated people-centered prevention, care and treatment services that will sustain HIV and TB epidemic control and reduce morbidity & mortality from preventable communicable & non-communicable diseases, including emerging public health threats in the districts of Maseru, Thaba Tseka, Mafeteng, and Mohale's Hoek. Bophelo Bo Botle activity is aligned to the USAID/Southern Africa Regional Development Strategy, the PEPFAR 5X3 strategic framework for ending AIDS by 2030, and the new GOL National Health Sector Strategic Plans. Inter-partner coordination with existing PEPFAR above-site implementing partners, other donor-funded programs, local faith and community-based organizations, and other local stakeholder is critical for program success. This activity will focus on three main overarching strategic priorities: a. Optimizing Clinical Service Delivery to improve access, quality, and utilization of integrated health services at the facility and community levels using a primary health care approach. b. Health systems strengthening support at district, facility, and community levels. c. Sustaining Local Capacity: Technical Assistance to enhance local capacity, ownership and governance frameworks that sustain enabling policy environments, transparency, accountability, and resource mobilization. Target populations are children, adolescents, youth, adults, pregnant and breastfeeding women, key populations, and communities in the Bophelo Bo Botle focus districts. Secondary target populations are health service providers at facility & community levels, private sector, faith- & community-based organizations, and policy makers at national and sub-national levels.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 72067424RFA00006 still open?
No. It closed on March 15, 2024.
Who can apply for USAID/Lesotho Bophelo Bo Botle (Good Health) Activity?
South Africa USAID-Pretoria accepted applications from any type of organization.
What is the deadline for USAID/Lesotho Bophelo Bo Botle (Good Health) Activity?
Closed March 15, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $18.3 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)